Phase 1 Study Finds Similar PK Between Eculizumab Biosimilar, Soliris

August 13, 2022

A phase 1 study compared pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity between SB12, a proposed eculizumab biosimilar, and EU and US reference products (Soliris) in healthy adults.

The Top 5 Biosimilar Articles for the Week of August 8
Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics
Prospective Study Finds Adalimumab Biosimilars Effective in IBD, but Fall Short of Infliximab Product
Review: Biosimilar-to-Biosimilar Switching Is Safe, Effective